Claims
- 1. The compound of structure:2,3,4,5,6-Pentafluorocinnamoyl-D-Arginine-Arginine-Proline-Trans-4-hydroxyproline-Glycine-α-2-Indanylglycine-Serine-D-α-2-Indanylglycine-Octahydroindole-2-carboxylic acid-Arginine or a pharmaceutically acceptable salt thereof.
- 2. The compound of the structure:2,3,4,5,6Pentafluorocinnamoyl-Lysine-Lysine-Arginine-Proline-Trans-4-hydoxyproline-Glycine-α-Cylcopentylglycine-Serine-D-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid-α-Cylcopentylglycine or a pharmaceutically acceptable salt thereof.
- 3. The compound of structure:2,3,4,5,6-Pentafluorocinnamoyl-D-ε-Nicotinoyllysine-4-(2-pyrazine carboxyl)ornithine Proline-Trans-4-hydroxyproline-Glycine-α-2-Indanylglycine-Serine-D-α-2-Indanylglycine-Octahydroindole-2-carboxylic acid-Arginine or a pharmaceutically acceptable salt thereof.
- 4. The compound of structure:2,3,4,5,6-Pentafluorocinnamoyl-p-Fluorophenylalanine-Arginine or a pharmaceutically acceptable salt thereof.
- 5. The compound comprising the structure:Dodecanedioyl-(D-Arginine-Pentaflurorphenylalanine-Arginine)2 or a pharmaceutically acceptable salt thereof.
- 6. The compound of structure:2,3,4,5,6-Pentafluorocinnamoyl-O-2,6-Dichlorobenzyltyrosine-4-Amino-2,2,6,6-tetramethylpiperidine or a pharmaceutically acceptable salt thereof.
- 7. The compound of structure:Dodecanedioyl-(D-Arginine-α-2-Indanylglycine-Arginine-4-(Methylamino)-2,2,6,6-tetramethylpiperidine)2 or a pharmaceutically acceptable salt thereof.
- 8. The compound comprising the structure:Ethylenediaminetetraacetyl-(O-2,6-Dichlorobenzyltyrosine-4-(Methylamino)-2,2,6,6-tetramethylpiperidine)4 or a pharmaceutically acceptable salt thereof.
- 9. The compound of structure:(5-dimethylamino-1-naphthalenesulfonyl-D-Arginine-α-2-Indanylglycine-Arginine)2-1,10-Decanediame or a pharmaceutically acceptable salt thereof.
- 10. The compound of structure:Dodecanedioyl-(D-Arginine-β-2Naphthylalanine-Arginine-4-(methylamino)-2,2,6,6-tetramethylpiperidine)2 or a pharmaceutically acceptable salt thereof.
- 11. The compound of structure:Decanedioyl-(-4-Aminocinnamic acid-α-2-Indanylglycine-4-amino-2,2,6,6-tetramethylpiperidine),(-Lysine-D-Arginine-Arginine-Proline-Trans-4-hydroxyproline-Glycine-α-2-Indanylglycine-Serine-D-α-2-Indanylglycine-Octrahydroindole-2-carboxylic acid-Arginine), or a pharmaceutically acceptable salt thereof.
Parent Case Info
The present application claims priority to U.S. Provisional Patent application Ser. No. 60/097,210, filed Aug. 20, 1998 and U.S. Provisional Patent application Ser. No. 60/141,169, filed Jun. 25, 1999.
GOVERNMENT RIGHTS
This invention was made in part with government support under grant numbers NIH HL-26284, awarded by the National Institutes of Health. The government has certain rights to this invention.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5635593 |
Cheronis et al. |
Jun 1997 |
A |
5849863 |
Stewart |
Dec 1998 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9709347 |
Mar 1997 |
WO |
Non-Patent Literature Citations (3)
Entry |
Stewart et al., Can. J. Physiol. Pharmacol. 75:719-724, 1997.* |
L. Gera, et al., “New Bradykinin Antagonists Having High Potency at Both B1 and B2 Receptors,” Peptides: Chemistry, Structure and Biology, Mayflower Scientific Ltd., 1996, pp. 348-349. |
D. Chan, et al., “Novel bradykinin antagonist dimers for the treatment of human lung cancers,” Immunopharmacology, vol. 33, 1996, pp. 201-204. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/097210 |
Aug 1998 |
US |
|
60/141169 |
Jun 1999 |
US |